Aidaro (Ebdarokimab) – Psoriasis | HongKong DengYue Medicine

Ebdarokimab Application Scope

• Moderate-to-severe Plaque Psoriasis in adults

• Patients not responding to, contraindicated for, or intolerant to systemic therapy

  

Ebdarokimab Characteristics

• Ingredients: Ebdarokimab

• Properties:​ Human monoclonal antibody targeting the IL-17 pathway

• Packaging Specification:​ 135 mg/vial, 1 vial/box

• Storage:​ Store at 2–8°C, protect from light

• Expiry Date: 24 months

• Executive Standard: ​National drug standard of China

• Approval Number: H20250021

• Date of Revision: 2025‑03

• Manufacturer: Akeso Biopharma

Guidelines for the Use of Aidaro

• Dosage and Administration:

  • Recommended Dose: 150 mg once every 2 weeks

  • Administration: Inject subcutaneously; rotate injection sites

  • Missed Dose:​ If a dose is missed, administer as soon as possible; do not double the next dose

• Adverse Reactions:

  • Common Adverse Reactions:

    • Injection site reactions

    • upper respiratory tract infections

    • headache

    • fatigue

  • Serious Adverse Reactions:

    • Severe infections
    • hypersensitivity reactions
    • neutropenia​

• Contraindications: Known hypersensitivity to it or any excipient

• Precautions:

  • Monitor for infections during treatment

  • Avoid use in patients with active infections

  • Use with caution in immunocompromised patients

Aidaro Interactions

• Avoid co-administration with other immunosuppressive biologics

• Monitor for additive risk of infections with concomitant immunosuppressive therapy

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.